^
Association details:
Biomarker:No biomarker
Cancer:Multiple Myeloma
Drug:bortezomib (Proteasome inhibitor) +
Empliciti (elotuzumab) (CS-1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
the NCCN Panel has included elotuzumab/bortezomib/dexamethasone as a treatment option for patients with relapsed/refractory MM... Multiple Myeloma: Therapy for previously treated multiple myeloma…Other Recommended Regimens…Elotuzumab/bortezomib/dexamethasone